STOCK TITAN

Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Codexis (NASDAQ: CDXS), a leading enzyme engineering company, will participate in the RNA Leaders annual meeting on September 4-5, 2024, in San Diego. The company will focus on using enzymes for scalable and cost-effective manufacturing of siRNA duplexes. Stefan Lutz, PhD, Codexis SVP of Research, will join a keynote panel discussing new solutions in RNA manufacturing. Another presentation will highlight ligation for joining siRNA fragments, reducing costs through higher yield and purity.

Codexis recently launched double-stranded RNA ligase screening and optimization services. Their presentation will showcase improvements in key ligase attributes using their ECO Synthesis™ manufacturing platform. These include high catalytic activity and improved performance on challenging sequences. Attendees can visit Codexis at Booth #9 or schedule appointments in advance.

Codexis (NASDAQ: CDXS), un'azienda leader nel campo dell'ingegneria enzimatica, parteciperà al meeting annuale RNA Leaders che si terrà il 4-5 settembre 2024 a San Diego. L'azienda si concentrerà sull'uso di enzimi per la produzione scalabile ed economica di duplex di siRNA. Stefan Lutz, PhD, Vicepresidente della Ricerca di Codexis, parteciperà a un panel di apertura che discuterà nuove soluzioni nella produzione di RNA. Un'altra presentazione metterà in evidenza la ligation per unire frammenti di siRNA, riducendo i costi attraverso un maggior rendimento e purezza.

Codexis ha recentemente lanciato i servizi di screening e ottimizzazione della ligasi di RNA a doppio filamento. La loro presentazione mostrerà i miglioramenti in attributi chiave della ligasi utilizzando la loro piattaforma di produzione ECO Synthesis™. Questi includono elevata attività catalitica e prestazioni migliorate su sequenze complesse. I partecipanti possono visitare Codexis presso lo Stand #9 o fissare appuntamenti in anticipo.

Codexis (NASDAQ: CDXS), una empresa líder en ingeniería enzimática, participará en la reunión anual de RNA Leaders que se llevará a cabo del 4 al 5 de septiembre de 2024 en San Diego. La empresa se concentrará en el uso de enzimas para la fabricación escalable y rentable de duplex de siRNA. Stefan Lutz, PhD, Vicepresidente Senior de Investigación de Codexis, se unirá a un panel principal para discutir nuevas soluciones en la fabricación de RNA. Otra presentación destacará la ligadura para unir fragmentos de siRNA, reduciendo costos a través de un mayor rendimiento y pureza.

Codexis recientemente lanzó servicios de selección y optimización de ligasas de RNA de doble hebra. Su presentación mostrará mejoras en características clave de la ligasa utilizando su plataforma de fabricación ECO Synthesis™. Estas incluyen alta actividad catalítica y un mejor rendimiento en secuencias difíciles. Los asistentes pueden visitar a Codexis en el Stand #9 o programar citas con anticipación.

Codexis (NASDAQ: CDXS), 선도적인 효소 엔지니어링 회사가 2024년 9월 4-5일 샌디에고에서 개최되는 RNA Leaders 연례 회의에 참여합니다. 이 회사는 siRNA 이중 가닥의 대량 생산 및 비용 효율적인 제조를 위한 효소 사용에 주안점을 두고 있습니다. Codexis의 연구 부사장인 Stefan Lutz 박사가 RNA 제조의 새로운 솔루션에 대한 기조 발제 패널에 참여할 예정입니다. 또 다른 발표에서는 siRNA 조각 결합을 위한 리가제를 강조하고, 더 높은 수율과 순도를 통해 비용을 절감하는 방법을 논의합니다.

Codexis는 최근 이중 가닥 RNA 리가제 스크리닝 및 최적화 서비스를 출시했습니다. 이 발표는 그들의 ECO Synthesis™ 제조 플랫폼을 사용하여 리가제의 주요 특성 개선을 보여줄 것입니다. 여기에는 높은 촉매 활성과 어려운 서열에 대한 개선된 성능이 포함됩니다. 참석자들은 Codexis를 부스 #9에서 방문하거나 사전 약속을 잡을 수 있습니다.

Codexis (NASDAQ: CDXS), une entreprise leader en ingénierie enzymatique, participera à la réunion annuelle des leaders en RNA du 4 au 5 septembre 2024 à San Diego. L'entreprise se concentrera sur l'utilisation des enzymes pour la fabrication évolutive et coût-efficace de duplexes de siRNA. Stefan Lutz, PhD, Vice-président de la recherche chez Codexis, participera à un panel de discours introductif sur les nouvelles solutions dans la fabrication de RNA. Une autre présentation mettra en lumière la ligation pour assembler des fragments de siRNA, réduisant ainsi les coûts grâce à des rendements et une pureté plus élevés.

Codexis a récemment lancé des services de dépistage et d'optimisation de ligases de RNA double brin. Leur présentation mettra en avant les améliorations des caractéristiques clés de la ligase grâce à leur plateforme de fabrication ECO Synthesis™. Cela inclut une haute activité catalytique et de meilleures performances sur des séquences difficiles. Les participants peuvent visiter Codexis au Stand #9 ou planifier des rendez-vous à l'avance.

Codexis (NASDAQ: CDXS), ein führendes Unternehmen in der Enzymtechnik, wird am Jahrestreffen der RNA Leaders am 4. und 5. September 2024 in San Diego teilnehmen. Das Unternehmen wird sich darauf konzentrieren, Enzyme für die skalierbare und kosteneffiziente Herstellung von siRNA-Duplexen zu nutzen. Stefan Lutz, PhD, Senior Vice President für Forschung bei Codexis, wird an einem Eröffnungspanel teilnehmen, das neue Lösungen in der RNA-Herstellung diskutiert. Eine weitere Präsentation wird die Ligierung zur Verbindung von siRNA-Fragmenten hervorheben, wobei die Kosten durch höhere Ausbeute und Reinheit gesenkt werden.

Codexis hat kürzlich Dienste zur Screening- und Optimierung von doppelsträngigen RNA-Ligasen eingeführt. Ihre Präsentation wird Verbesserungen in wichtigen Eigenschaften der Ligase unter Verwendung ihrer ECO Synthesis™-Fertigungstechnologie präsentieren. Dazu gehören eine hohe katalytische Aktivität und eine verbesserte Leistung bei anspruchsvollen Sequenzen. Teilnehmer können Codexis am Stand #9 besuchen oder im Voraus Termine vereinbaren.

Positive
  • None.
Negative
  • None.

REDWOOD CITY, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a presentation and panel discussion at the upcoming RNA Leaders annual meeting, being held September 4-5, 2024, in San Diego, CA. The Company’s presentations will focus on the use of enzymes to drive the scalable and cost-effective manufacture of short inhibitory ribonucleic acid (siRNA) duplexes.

During a keynote panel presentation, Stefan Lutz, PhD, Codexis Senior Vice President of Research, in addition to other RNA industry leaders, will discuss how the biopharmaceutical industry is developing new solutions to advance RNA manufacturing, address production capacities and establish new approaches to streamline clinical trials and standardize protocols.

The Company’s second presentation will focus on ligation, which enables the joining of siRNA fragments to generate full-length siRNA duplexes. This approach reduces the overall costs of siRNA manufacturing by leveraging the inherent benefits of short fragment synthesis, including higher yield and increased purity. Codexis recently launched its double-stranded RNA ligase screening and optimization services, and the Company’s presentation will demonstrate improvements across key ligase attributes critical for siRNA manufacturing utilizing its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ manufacturing platform. These include high catalytic activity at high substrate loading, as well as improved performance on challenging sequences and modification near ligation junctions. Additionally, improvements in manufacturability of double-stranded RNA ligases are expected to result in a more reliable and scalable enzyme supply.

Attendees of the conference may visit with the Codexis team at Booth #9 in the exhibition hall. Appointments may be made in advance by clicking here.

Presentation Details

Keynote Panel: Scaling RNA Therapies to Deliver on the Promise of Precision Medicine
Date: Wednesday, September 4, 2024
Time: 10:15 – 10:55 am Pacific Daylight Time (PDT)
Location: San Diego Convention Center, San Diego, CA
Codexis Speaker: Stefan Lutz, PhD, Senior Vice President of Research

Presentation Title: Cost-effective Manufacturing of siRNA Duplexes at High Yield and Purity Using Engineered Double-stranded RNA Ligases
Date: Wednesday, September 4, 2024
Time: 11:45 am – 12:10 pm Pacific Daylight Time (PDT)
Location: San Diego Convention Center, San Diego, CA
Codexis Speaker: Mathew Miller, PhD, Director, Life Science & RNA Technology

About RNAi Therapeutics Manufacturing

Ribonucleic acid (RNA) as a therapeutic modality has gained tremendous traction in recent years with the growing number of messenger RNA (mRNA) vaccines and small interfering RNA (siRNA) candidates advancing in clinical studies. However, large-scale production of RNA interference (RNAi) therapeutics using traditional chemical synthesis faces complex challenges in nucleic acid quality and quantity, as well as overall economics. With over 450 RNAi therapies currently in clinical development, including more than 40 assets in Phase 2 and Phase 3 clinical trials targeting disease indications impacting millions of patients, RNAi therapeutic demand is projected to outpace current production capabilities by the end of the decade.

About the ECO Synthesis™ Manufacturing Platform

Codexis’ proprietary Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ manufacturing platform is being designed to address these scalability and cost limitations by potentially enabling the commercial-scale manufacture of RNAi therapeutics through an enzymatic route. The Company presented groundbreaking data at the TIDES USA 2024 annual meeting demonstrating the enzymatic synthesis of a full-length sense strand of the oligonucleotide lumasiran, a commercially available siRNA therapeutic, as well as shorter sense strand fragments of a second siRNA therapeutic asset, givosiran. The data demonstrate that Codexis consistently achieved coupling efficiency greater than 98%, which is equivalent to what is seen with phosphoramidite chemistry; executed the enzymatic addition of a conjugation moiety to the lumasiran strand; and confirmed the lack of notable impurities typically observed in oligonucleotide synthesis via phosphoramidite chemistry. A recording of the presentation, along with slides and the data press release, can be found on the Codexis corporate website.

About Codexis

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “suggest,” “target,” “on track,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management, including, but not limited to, the ability of an enzymatic oligonucleotide synthesis process to complement or replace traditional chemical synthesis; the potential of the Company’s ECO Synthesis™ platform and double-stranded RNA (dsRNA) ligase screening and optimization services to create value for Codexis and its customers by enabling commercial-scale manufacture of RNAi therapeutics; other anticipated technical and commercial milestones related to the ECO Synthesis™ platform and the dsRNA ligase program, and public announcements related thereto; potential details and features of the ECO Synthesis™ platform such as it being scalable and able to reduce manufacturing costs, as well as having higher purity and yield than existing methods; and the future demand for RNAi therapeutics. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis’ dependence on its licensees and collaborators; if any of its collaborators terminate their development programs under their respective license agreements with Codexis; Codexis may need additional capital in the future in order to expand its business; if Codexis is unable to successfully develop new technology such as its ECO Synthesis™ manufacturing platform and dsRNA ligase; Codexis’ dependence on a limited number of products and customers, and potential adverse effects to Codexis’ business if its customers’ products are not received well in the markets; whether the end markets for Codexis’ customers’ products develop and remain viable; if Codexis is unable to develop and commercialize new products for its target markets; whether the end markets for Codexis’ customers’ products develop and remain viable; if competitors and potential competitors who have greater resources and experience than Codexis develop products and technologies that make Codexis’ products and technologies obsolete; Codexis’ ability to comply with debt covenants under its loan facility; if Codexis is unable to accurately forecast financial and operational performance; and market and economic conditions may negatively impact Codexis business, financial condition and share price. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) on February 28, 2024 and in Codexis’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the SEC on August 8, 2024, including under the caption “Risk Factors,” and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

For More Information

Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com

Media Contact
Lauren Musto
(781) 572-1147
media@codexis.com


FAQ

What is Codexis presenting at the RNA Leaders annual meeting in 2024?

Codexis (CDXS) is presenting on enzymatic synthesis for siRNA duplex manufacturing and participating in a keynote panel on RNA manufacturing solutions at the RNA Leaders annual meeting on September 4-5, 2024, in San Diego.

How does Codexis aim to reduce siRNA manufacturing costs?

Codexis aims to reduce siRNA manufacturing costs by using ligation to join siRNA fragments, leveraging the benefits of short fragment synthesis for higher yield and increased purity.

What new service has Codexis recently launched for RNA synthesis?

Codexis has recently launched double-stranded RNA ligase screening and optimization services to improve siRNA manufacturing using their ECO Synthesis™ manufacturing platform.

When and where will Stefan Lutz from Codexis speak at the RNA Leaders meeting?

Stefan Lutz, PhD, Codexis SVP of Research, will speak in a keynote panel on September 4, 2024, from 10:15 - 10:55 am PDT at the San Diego Convention Center.

What improvements in ligase attributes will Codexis demonstrate at the RNA Leaders meeting?

Codexis will demonstrate improvements in high catalytic activity at high substrate loading and improved performance on challenging sequences and modifications near ligation junctions for siRNA manufacturing.

Codexis, Inc.

NASDAQ:CDXS

CDXS Rankings

CDXS Latest News

CDXS Stock Data

221.29M
70.93M
2.34%
78%
2.87%
Biotechnology
Industrial Organic Chemicals
Link
United States of America
REDWOOD CITY